131 related articles for article (PubMed ID: 361463)
1. Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients.
Slama G; Selmi A; Hautecouverture M; Tchobroutsky G
Diabete Metab; 1978 Sep; 4(3):193-9. PubMed ID: 361463
[TBL] [Abstract][Full Text] [Related]
2. A double blind controlled trial of a new anorectic agent AN448.
Woodhouse SP; Nye ER; Anderson K; Rawlings J
N Z Med J; 1975 Jun; 81(542):546-9. PubMed ID: 1099491
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
[TBL] [Abstract][Full Text] [Related]
4. AN 448 Sandoz (Mazindol) in the treatment of obesity.
Wallace AG
Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265
[TBL] [Abstract][Full Text] [Related]
5. Weight reduction versus antihypertensive drug therapy in obese men with high blood pressure: effects upon plasma insulin levels and association with changes in blood pressure and serum lipids.
Fagerberg B; Berglund A; Andersson OK; Berglund G
J Hypertens; 1992 Sep; 10(9):1053-61. PubMed ID: 1328365
[TBL] [Abstract][Full Text] [Related]
6. Double-blind clinical evaluation of mazindol (42-548) in obese diabetics.
Bandisode MS; Boshell BR
Curr Ther Res Clin Exp; 1975 Dec; 18(6):816-24. PubMed ID: 813947
[No Abstract] [Full Text] [Related]
7. Investigation of insulin sensitivity in early diabetes III. The effect of a combined physical training and diet programme on body weight, serum lipids and insulin sensitivity in obese asymptomatic diabetics.
Ratzmann KP; Zander E; Witt S; Schulz B
Endokrinologie; 1981 Apr; 77(2):233-41. PubMed ID: 7262046
[TBL] [Abstract][Full Text] [Related]
8. [Glucose tolerance, insulin and lipids after one week's administration of fenfluramine to overweight patients (author's transl)].
Weisweiler P; Schwandt P
MMW Munch Med Wochenschr; 1975 Nov; 117(48):1925-8. PubMed ID: 813120
[TBL] [Abstract][Full Text] [Related]
9. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
10. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
12. A double-blind trial of mazindol using a very low calorie formula diet.
Baird IM; Howard AN
Int J Obes; 1977; 1(3):271-8. PubMed ID: 363631
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].
Riesco J; Troncoso G; Costamaillere L; Rodríguez J
Rev Med Chil; 1977 Jun; 105(6):375-9. PubMed ID: 331428
[No Abstract] [Full Text] [Related]
14. Treatment of obesity: comparison of physician and nonphysician therapists using placebo and anorectic drugs in a double-blind trial.
Atkinson RL; Greenway FL; Bray GA; Dahms WT; Molitch ME; Hamilton K; Rodin J
Int J Obes; 1977; 1(2):113-20. PubMed ID: 363629
[TBL] [Abstract][Full Text] [Related]
15. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
[TBL] [Abstract][Full Text] [Related]
16. The effect of mazindol on metabolic and regulatory changes in obese women during weight reduction.
Rath R; Vondra K; Bass A; Kujalova V; Wenkeova J
Int J Obes; 1979; 3(2):133-40. PubMed ID: 93588
[TBL] [Abstract][Full Text] [Related]
17. A multicentre study comparing mazindol and placebo in obese patients.
Walker BR; Ballard IM; Gold JA
J Int Med Res; 1977; 5(2):85-90. PubMed ID: 326596
[TBL] [Abstract][Full Text] [Related]
18. Effect of mazindol on body weight and insulin sensitivity in severely obese patients after a very-low-calorie diet therapy.
Nishikawa T; Iizuka T; Omura M; Kuramoto N; Miki T; Ito H; Chiba S
Endocr J; 1996 Dec; 43(6):671-7. PubMed ID: 9075607
[TBL] [Abstract][Full Text] [Related]
19. The effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in Cameroon.
Ngondi JL; Oben JE; Minka SR
Lipids Health Dis; 2005 May; 4():12. PubMed ID: 15916709
[TBL] [Abstract][Full Text] [Related]
20. The effect of an anorectic agent (Mazindol) on control of obese diabetics.
Sanders M; Breidahl H
Med J Aust; 1976 Oct; 2(15):576-7. PubMed ID: 994969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
